Navigation Links
Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
Date:2/26/2013

AUSTIN, Texas, Feb. 26, 2013 /PRNewswire/ -- Savara Pharmaceuticals today announced the formation of its Clinical Advisory Board to provide clinical guidance to the company as it advances the development of its lead product, AeroVanc™ for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in patients with cystic fibrosis (CF).

The Clinical Advisory Board is comprised of five prominent thought leaders within the cystic fibrosis and infectious disease communities. These individuals will provide clinical knowledge and strategic guidance, as well as assist Savara in establishing deeper relationships with the CF care community in the U.S.

"We have seen MRSA lung infection grow rapidly in the CF population in recent years, and the negative effects of MRSA on lung function and the lifespan of CF patients are now well recognized," said Elliott Dasenbrook , M.D., M.H.S., Associate Director of the Adult Cystic Fibrosis Program at University Hospitals Case Medical Center.

"Savara's AeroVanc takes a proven antibiotic and combines it with an easy to use dry powder inhaler; an important step forward in addressing this significant unmet clinical need," Dr. Dasenbrook continued. Dr. Dasenbrook, the lead author of a ground breaking study in 2010 showing CF patients with persistent MRSA infection have a significantly shorter life expectancy, will act as the lead investigator for Savara's upcoming Phase II trial.

"We are very pleased to have this group of preeminent medical professionals join our Clinical Advisory Board," said Rob Neville , CEO of Savara Pharmaceuticals. "These individuals have decades of experience in the field and will provide invaluable counsel as we advance our AeroVanc clinical program this year and beyond. Their commitment to assist us in the development of AeroVanc speaks to the high importance our product may have for CF patients."

Savara plans to start enrollment in its Phase II clinical trial of AeroVanc in early April 2013. The trial is a randomized, double-blind, placebo-controlled study carried out in multiple sites around the U.S.

Members of the Clinical Advisory Board

Michael P. Boyle , M.D., F.C.C.P., Associate Professor of Medicine and Director of the Adult Cystic Fibrosis Program at Johns Hopkins Medical Institutions, Baltimore, MD.

Elliott C. Dasenbrook , M.D., M.H.S., Assistant Professor at Case Western Reserve University School of Medicine, Associate Director of the Adult Cystic Fibrosis Program at University Hospitals Case Medical Center, Cleveland, OH.

Michael W. Konstan , M.D., Professor and Chairman of the Department of Pediatrics of Case Western Reserve University School of Medicine, Director of The LeRoy W. Matthews Cystic Fibrosis Center at University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH.

Felix Ratjen , M.D., F.R.C.P.(C), Professor and Division Chief of Pediatric Respiratory Medicine at The Hospital for Sick Children, Co-leader of the Cystic Fibrosis Center at SickKids, Toronto, Canada.

Grant Waterer , M.B.B.S., F.R.A.C.P., Professor and Head of Unit at the School of Medicine and Pharmacology Royal Perth Hospital Unit at the University of Western Australia, Perth, Australia.

About AeroVanc™
AeroVanc™ (vancomycin hydrochloride inhalation powder) is a proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. AeroVanc is being developed for the treatment of MRSA lung infection in CF patients. Vancomycin administered by IV is the antibiotic of choice for the treatment of MRSA-related bronchopneumonia, however, IV administration, poor penetration into the lungs and systemic toxicities limits its use in a chronic setting. By delivering vancomycin directly to the site of infection, AeroVanc is expected to improve clinical efficacy and reduce adverse effects due to systemic drug exposure.

AeroVanc has demonstrated positive safety and tolerability in Phase I clinical studies conducted in healthy subjects and CF patients, with a pharmacokinetic profile that supports its potential as a twice-daily treatment for pulmonary MRSA infection.

About Cystic Fibrosis and MRSA 
Cystic fibrosis is a life-shortening genetic disease characterized by thick, sticky mucus in the lungs and frequent lung infections, which result in loss of lung function. As the disease progresses, the lungs of CF patients are typically infected with bacteria that are difficult to eradicate. Such infections are usually treated with inhaled antibiotics. In recent years, infection by MRSA has become increasingly common, with a prevalence of almost 30 percent of the estimated 30,000 CF patients in the United States. Persistent MRSA lung infection is associated with faster decline in lung function and a significantly shortened life expectancy. Currently there is no approved inhaled therapy for MRSA lung infection for CF patients.

About Savara Pharmaceuticals 
Savara Pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. The company's lead product, AeroVanc™ (vancomycin hydrochloride inhalation powder), is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis. For more information, please see Savara's website at www.savarapharma.com.


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
2. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
3. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
4. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
5. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
6. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
7. Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Response to Citizens Petition
8. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
9. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
10. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
11. Webcast Alert: Isis Pharmaceuticals 2012 Financial Results and Highlights Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... 2017 , ... On Saturday, October 21, the Health & Wellness Center at ... raise money for the American Heart Association Heart Walk. Teams of up to 10 ... to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. ...
Breaking Medicine News(10 mins):